



New York State Medicaid Drug Utilization Review (DUR) Board Meeting

The DUR Board is scheduled to meet on December 15, 2022, from 10:00 am to 2:00 pm
Meeting Room 5, Concourse Level, Empire State Plaza, Albany NY
Albany, New York.

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

This meeting will also be available for public viewing from the:

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall - Room 130
Buffalo, NY 14214

SUNY Global Center
116 East 55th Street, New York, NY 10022

St. John Fisher University
James S. Alesi Academic Center - Room 104
Rochester, NY 14618

Agenda Items

A. Drug Utilization Review

The DUR Board will review the following drugs and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Risdiplam (Evrysdi®)
2. Nusinersen (Spinraza®)
3. Ocrelizumab (Ocrevus®)
4. Betibeglogene autotemcel (Zynteglo®)

B. Pharmacy Program Updates

The DUR Board will be provided updates on the following topics:

1. Medicaid Prescriber Education Program - [MPEP](#)
2. Hepatitis C Virus – Utilization of Direct Acting Antivirals - [FFS PDP](#)

Agenda Timeline (subject to change based on meeting proceedings)

10:00 – 10:15	Welcome, Introductions and Opening Comments
10:15 – 11:15	Public Comment Period
11:15 – 1:15	Drug Utilization Reviews
1:15 – 1:45	Pharmacy Program Updates
1:45 – 2:00	Closing Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by December 7, 2022. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by December 7, 2022. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by November 30, 2022, or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.